Protective vascular and myocardial effects of adiponectin

Nature Clinical Practice Cardiovascular Medicine

Volumn 6, Issue 1, 2009, Pages 27-35

  Goldstein, Barry J ^a   Scalia, Rosario G ^b   Ma, Xin L ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL PROTECTION; CELL SURVIVAL; ENDOTHELIUM CELL; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MICROVASCULATURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ADIPONECTIN; ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROVESSELS; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; PROTEIN CONFORMATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 58049196713     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1398     Document Type: Review

References (68)

1. Goldstein BJ and Scalia R (2007) Adipokines and vascular disease in diabetes. Curr Diab Rep 7: 25-33
2. Zhu W et al. (2008) Vascular effects of adiponectin: Molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 114: 361-374
3. Jay D et al. (2006) Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 40: 183-192
4. Granger DN et al. (2004) Modulation of the inflammatory response in cardiovascular disease. Hypertension 43: 924-931
5. Ouchi N et al. (2003) Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42: 231-234
6. Shimabukuro M et al. (2003) Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 88 3236-3240
7. Tan KC et al. (2004) Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 89: 765-769
8. Fernandez-Real JM et al. (2004) Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care 27: 739-745
9. Halperin F et al. (2005) The role of total and high-molecular-weight complex of adiponectin in vascular function in offspring whose parents both had type 2 diabetes. Diabetologia 48: 2147-2154
10. Kubota N et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277: 25863-25866
11. Matsuda M et al. (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277: 37487-37491
12. Okamoto Y et al. (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106: 2767-2770
13. Yamauchi T et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278: 2461-2468
14. Ohashi K et al. (2006) Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47: 1108-1116
15. Okamoto Y et al. (2000) An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32: 47-50
16. Shibata R et al. (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMP kinase-and COX-2-dependent mechanisms. Nat Med 11: 1096-1103
17. Tao L et al. (2007) Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115: 1408-1416
18. Scherer PE (2006) Adipose tissue: From lipid storage compartment to endocrine organ. Diabetes 55: 1537-1545
19. Wang Y et al. (2002) Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 277: 19521-19529
20. Pajvani UB et al. (2003) Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278: 9073-9085
21. Schraw T et al. (2008) Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology 149: 2270-2282
22. Neumeier M et al. (2006) Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol 79: 803-808
23. Fruebis J et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98: 2005-2010
24. Ouedraogo R et al. (2007) Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 117: 1718-1726
25. Hopkins TA et al. (2006) Adiponectin actions in the cardiovascular system. Cardiovasc Res 74: 11-18
26. Waki H et al. (2005) Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 146: 790-796
27. Kadowaki T et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784-1792
28. Ouedraogo R et al. (2006) Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: Evidence for involvement of a cAMP signaling pathway. Diabetes 55: 1840-1846
29. Motoshima H et al. (2004) Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 315: 264-271
30. Ding G et al. (2007) Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor γ. J Mol Cell Cardiol 43: 73-84
31. Hug C et al. (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101: 10308-10313
32. Williams JK et al. (1988) Vasa vasorum in atherosclerotic coronary arteries: Responses to vasoactive stimuli and regression of atherosclerosis. Circ Res 62: 515-523
33. Herrmann J et al. (2001) Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc Res 51: 762-766
34. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874
35. Moulton KS (2006) Angiogenesis in atherosclerosis: Gathering evidence beyond speculation. Curr Opin Lipidol 17: 548-555
36. Lautamaki R et al. (2007) Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 56 881-886
37. Furukawa S et al. (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761
38. Brownlee M (2005) The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54: 1615-1625
39. Rask-Madsen C and King GL (2007) Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3: 46-56
40. Ouchi N et al. (1999) Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 100: 2473-2476
41. Ouchi N et al. (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102: 1296-1301
42. Xu SQ et al. (2008) Adiponectin protects against angiotensin II or tumor necrosis factor alpha-induced endothelial cell monolayer hyperpermeability: Role of cAMP/PKA signaling. Arterioscler Thromb Vasc Biol 28: 899-905
43. Chen H et al. (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278: 45021-45026
44. Hattori Y et al. (2003) Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 46 1543-1549
45. Xi W et al. (2005) Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: Vasorelaxation in response to globular adiponectin. Biochem Biophys Res Commun 332: 200-205
46. Kobayashi H et al. (2004) Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94: E27-e31
47. Ouchi N et al. (2004) Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279: 1304-1309
48. Kadowaki T et al. (2007) The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett 582: 74-80
49. Goldstein BJ and Scalia R (2004) Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 2563-2568
50. Wu X et al. (2007) Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: Role of cAMP and AMP kinase signaling. Am J Physiol Endocrinol Metab 293: E1836-E1844
51. Mahadev K et al. (2008) Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells. Cardiovasc Res 78: 376-384
52. Collins SP et al. (2000) LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem J 345: 673-680
53. Shibata R (2004) Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling. J Biol Chem 279: 28670-28674
54. Brååkenhielm E et al. (2004) Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 101: 2476-2481
55. Bora PS et al. (2007) Expression of adiponectin in choroidal tissue and inhibition of laser induced choroidal neovascularization by adiponectin. FEBS Lett 58: 1977-1982
56. Natarajan R et al. (2008) Hypoxia inducible factor-1 upregulates adiponectin in diabetic mouse hearts and attenuates post-ischemic injury. J Cardiovasc Pharmacol 51: 178-187
57. Date H et al. (2006) Adiponectin produced in coronary circulation regulates coronary flow reserve in nondiabetic patients with angiographically normal coronary arteries. Clin Cardiol 29: 211-214
58. Sharma K et al. (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118: 1645-1656
59. Frystyk, J et al. (2005) Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48: 1911-1918
60. Schalkwijk CG et al. (2005) Adiponectin is inversely associated with renal function in Type 1 diabetic patients. J Clin Endocrinol Metab 91: 129-135
61. Koshimura J et al. (2004) Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun 316: 165-169
62. Shinmura K et al. (2007) Cardioprotective effects of short-term caloric restriction are mediated by adiponectin via activation of AMP-activated protein kinase. Circulation 116: 2809-2817
63. Ikeda Y et al. (2008) Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FEBS Lett 582: 1147-1150
64. Gao F et al. (2002) Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105: 1497-1502
65. Li R et al. (2007) Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab 293: E1703-E1708
66. Kim YM et al. (1999) Nitric oxide as a bifunctional regulator of apoptosis. Circ Res 84: 253-256
67. Beckman JS and Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol 271 C1424-C1437
68. Ferdinandy P et al. (2000) Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87 241-247